- Home
- NRO vs BIOA Comparison
NRO vs BIOA Comparison
Compare NRO & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRO
- BIOA
- Stock Information
- Founded
- NRO 2003
- BIOA 2015
- Country
- NRO United States
- BIOA United States
- Employees
- NRO N/A
- BIOA N/A
- Industry
- NRO Finance/Investors Services
- BIOA Biotechnology: Pharmaceutical Preparations
- Sector
- NRO Finance
- BIOA Health Care
- Exchange
- NRO Nasdaq
- BIOA Nasdaq
- Market Cap
- NRO 187.8M
- BIOA 177.1M
- IPO Year
- NRO N/A
- BIOA 2024
- Fundamental
- Price
- NRO $3.59
- BIOA $5.14
- Analyst Decision
- NRO
- BIOA Hold
- Analyst Count
- NRO 0
- BIOA 3
- Target Price
- NRO N/A
- BIOA $18.00
- AVG Volume (30 Days)
- NRO 239.4K
- BIOA 959.0K
- Earning Date
- NRO 01-01-0001
- BIOA 02-15-2025
- Dividend Yield
- NRO 11.41%
- BIOA N/A
- EPS Growth
- NRO N/A
- BIOA N/A
- EPS
- NRO N/A
- BIOA N/A
- Revenue
- NRO N/A
- BIOA N/A
- Revenue This Year
- NRO N/A
- BIOA N/A
- Revenue Next Year
- NRO N/A
- BIOA N/A
- P/E Ratio
- NRO N/A
- BIOA N/A
- Revenue Growth
- NRO N/A
- BIOA N/A
- 52 Week Low
- NRO $2.51
- BIOA $3.85
- 52 Week High
- NRO $3.45
- BIOA $26.62
- Technical
- Relative Strength Index (RSI)
- NRO 50.96
- BIOA N/A
- Support Level
- NRO $3.45
- BIOA N/A
- Resistance Level
- NRO $3.64
- BIOA N/A
- Average True Range (ATR)
- NRO 0.08
- BIOA 0.00
- MACD
- NRO 0.02
- BIOA 0.00
- Stochastic Oscillator
- NRO 76.00
- BIOA 0.00
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. The fund invests in sectors, such as apartments, Data Centers, Infrastructure REITs, Manufactured Homes, Office, Regional Malls and others.
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.